GQ1007 / GeneQuantum Healthcare, BrighGene - LARVOL DELTA

GQ1007: the next generation HER2-targeting antibody immune agonist conjugate with robust efficacy and favorable safety profile (SITC 2023) - "Importantly, our data strongly indicate a high potential for a favorable safety profile for GQ1007, highlighting its suitability for clinical exploration as a monotherapy or as a combination treatment with the existing ICI therapies. In conclusion, GQ1007 holds a great promise as a novel and effective treatment option for advanced HER2-expressing patients."

Clinical • IO biomarker • Oncology • CD8 • HER-2 • TNFA

GeneQuantum Healthcare’s Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia (PRNewswire) - "GeneQuantum Healthcare (Suzhou)...announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights."

New trial • Oncology

A First-In-Human, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid Tumors (ANZCTR) - P1 | N=200 | Not yet recruiting | Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd.

Combination therapy • New P1 trial • Breast Cancer • Cholangiocarcinoma • Esophageal Cancer • Gallbladder Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • HER2 Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

Regulatory Considerations for ADCs (ADC London 2022) - "HER2 is a proven target for breast cancer, gastric cancer and other solid tumours GQ1007 is HER2 AIAC that has been developed using GeneQuantum’s unique iLDC bioconjugation platform, leading excellent druggability and linker stability Review how GQ1007 demonstrates robust in vitro and in vivo anti-tumour activities in multiple preclinical models Evaluate how GQ1007 has the potential to become an important therapeutic option for the HER2+ patients who have progressed on current standard therapies, and a combo opportunity with PD1 therapy"

Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

Preclinical Development of CQ1007, HER2 Ab Immune Agonist Conjugate (AIAC) With the Best-in-Class Potential (ADC London 2022) - "HER2 is a proven target for breast cancer, gastric cancer and other solid tumours GQ1007 is HER2 AIAC that has been developed using GeneQuantum’s unique iLDC bioconjugation platform, leading excellent druggability and linker stability Review how GQ1007 demonstrates robust in vitro and in vivo anti-tumour activities in multiple preclinical models Evaluate how GQ1007 has the potential to become an important therapeutic option for the HER2+ patients who have progressed on current standard therapies, and a combo opportunity with PD1 therapy"

Preclinical • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

[VIRTUAL] Preclinical Development of GQ1007, HER2 Ab Immune Agonist Conjugate (AIAC) with the Best-in-class Potential (ADC-USA 2021) - "HER2 is a proven target for breast cancer, gastric cancer and other solid tumors GQ1007 is HER2 AIAC that has been developed using GeneQuantum’s unique iLDC bioconjugation platform, leading to excellent druggability and linker stability GQ1007 demonstrates robust in vitro and in vivo anti-tumor activities in multiple preclinical models Discuss GQ1007’s potential to become an important therapeutic option for the HER2+ patients who have progressed on current standard therapies, and a combo opportunity with PD1 therapy Lunch"

Preclinical • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates (PRNewswire-Asia) - "GeneQuantum Healthcare (Suzhou) Co.,Ltd...and BrighGene Biomedical (Suzhou) Co.,Ltd...signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007. GQ1007 is a new type of antibody-drug conjugate. It is an antibody conjugated to a potent immune agonist...GQ 1007 achieves strong and lasting anti-tumor effect, overcomes the low response rate of PD-1 antibody in immunotherapy, and has great clinical value and market potential."

Licensing / partnership • Oncology